Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Windtree Therapeutics ( (WINT) ) has provided an announcement.
On June 18, 2025, Windtree Therapeutics received a deficiency letter from Nasdaq, indicating that the company’s stock price had been below the required $1.00 minimum for 30 consecutive business days. Due to previous reverse stock splits, the company is not eligible for the standard compliance period and must request a hearing by June 25, 2025, to avoid suspension or delisting. The company plans to request this hearing, which will temporarily prevent suspension or delisting while awaiting a decision. However, there is no guarantee that an extension will be granted or that compliance will be regained.
The most recent analyst rating on (WINT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. operates in the biotechnology industry, focusing on developing novel therapeutics for acute cardiovascular and pulmonary conditions.
Average Trading Volume: 2,751,938
Technical Sentiment Signal: Sell
Current Market Cap: $2.01M
Learn more about WINT stock on TipRanks’ Stock Analysis page.